Global Atherosclerosis Drugs Market Growth, Size, Share, Industry Report and Forecast 2021-2027
The global atherosclerosis drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). The rise in the prevalence of atherosclerosis and cardiovascular disorders is a major factor driving the market’s growth. According to the European Heart Network, cardiovascular disease kills 3.9 million people in Europe each year, with over 1.8 million people dying in the European Union. In wealthy countries, sedentary lifestyles are responsible for the highest rates of cardiovascular disease. Sedentary behaviour is associated with a high prevalence of high blood pressure, high cholesterol, obesity, and excessive alcohol intake, all of which contribute to an increased risk of cardiovascular disease. As a result, the market examined is predicted to be driven by a sedentary lifestyle resulting in a high prevalence of cardiovascular illnesses and rising awareness of treatment choices.
Statins and fibrates are two types of cholesterol-lowering medicines. The
growing prevalence of cardiovascular disease, high cholesterol, and obesity
globally is responsible for the segment's dominance. In 2018, the World Health
Organization (WHO) predicted that 40 million children under the age of five
were overweight or obese. Increased consumption of high-fat, high-sugar foods,
as well as an increase in physical immobility due to the increasingly inactive
nature of many types of work, changing modes of transportation, and increasing
urbanization, are all contributing to high cholesterol rates and, as a result,
segment growth.
To Request a Sample of our Report on Global
Atherosclerosis Drugs Market: https://www.omrglobal.com/request-sample/atherosclerosis-drugs-market
In addition, the approval of new
cholesterol-lowering medications is boosting the market growth. For instance,
the pharmaceuticals alirocumab (Praluent) and evolocumab (Repatha) are part of
a novel class of treatments known as PCSK9 inhibitors, which reduce dangerous
LDL cholesterol levels by more than 50%. Novel therapeutic medications like
this help to drive segment growth. The segment's growth is aided by an
expanding patient pool and increased approvals of new medications.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: Pfizer
Inc., AstraZeneca, Merck & Co., Inc., Sanofi US, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Global Atherosclerosis Drugs Market is Available at: https://www.omrglobal.com/industry-reports/atherosclerosis-drugs-market
Global Atherosclerosis Drugs Market by Segments
By Drug Class
• Anti-Platelet
Medications
• Cholesterol-Lowering
Medications
• Fibric Acid and Omega-3
Fatty Acid Derivatives
• Beta Blockers
• Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Global Atherosclerosis Drugs Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion
Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment